rs199473225
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PP2PP3_StrongPP5_Very_Strong
The NM_001099404.2(SCN5A):c.3995C>T(p.Pro1332Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 14/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. P1332P) has been classified as Benign.
Frequency
Consequence
NM_001099404.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN5A | NM_001099404.2 | c.3995C>T | p.Pro1332Leu | missense_variant | 23/28 | ENST00000413689.6 | NP_001092874.1 | |
SCN5A | NM_000335.5 | c.3992C>T | p.Pro1331Leu | missense_variant | 23/28 | ENST00000423572.7 | NP_000326.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN5A | ENST00000413689.6 | c.3995C>T | p.Pro1332Leu | missense_variant | 23/28 | 5 | NM_001099404.2 | ENSP00000410257 | P4 | |
SCN5A | ENST00000423572.7 | c.3992C>T | p.Pro1331Leu | missense_variant | 23/28 | 1 | NM_000335.5 | ENSP00000398266 | A1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 02, 2022 | Reported in association with LQTS in patients referred to GeneDx and in published literature (Schulze-Bahr et al., 2004; Ruan et al., 2007; Berge et al., 2008; Liu et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate a gain-of-function effect as the P1332L variant channel shows a negative voltage shift in steady state inactivation, delayed inactivation, and a more than two-fold increased late sodium current, compared to wild-type channel (Ruan et al., 2007; Liu et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29791480, 24136861, 30662450, 23631430, 17698727, 14676229, 18752142) - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Jul 29, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 27, 2022 | ClinVar contains an entry for this variant (Variation ID: 67844). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects SCN5A function (PMID: 17698727). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This missense change has been observed in individual(s) with long QT syndrome (LQTS) (PMID: 14676229, 17698727, 18752142, 23631430). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1332 of the SCN5A protein (p.Pro1332Leu). - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Jun 17, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 04, 2022 | - - |
Long QT syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 03, 2020 | Variant summary: SCN5A c.3995C>T (p.Pro1332Leu) results in a non-conservative amino acid change located in the Ion transport domain (IPR005821) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251040 control chromosomes (gnomAD). c.3995C>T has been reported in the literature in multiple individuals affected with Long QT Syndrome and Brugada Syndrome (e.g. Ruan_2007, Riuro_2015, Liu_2018, Shimizu_2019). These data indicate that the variant is very likely to be associated with disease. Publications also reported experimental evidence evaluating an impact on protein function, and demonstrated slower inactivation and prominent late Na+ currents (Ruan_2007, Liu_2018). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 15, 2023 | The p.P1332L pathogenic mutation (also known as c.3995C>T), located in coding exon 22 of the SCN5A gene, results from a C to T substitution at nucleotide position 3995. The proline at codon 1332 is replaced by leucine, an amino acid with similar properties. This alteration was reported to occur de novo in a patient with long QT syndrome (LQTS) presenting first with fetal bradycardia and tachycardia as well as third degree AV block, prolonged QT interval, and non-sustained polymorphic ventricular tachycardia as an infant (Schulze-Bahr E et al. Heart. 2004;90:13-6). Another study reported this alteration in two unrelated individuals with LQTS, and in vitro studies indicated abnormal ion channel function as a result of this alteration (Ruan Y et al. Circulation. 2007;116:1137-44). This alteration was also reported in a Brugada syndrome cohort; howevver, clinical details were limited (Kapplinger JD et al. Heart Rhythm. 2010;7:33-46). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Brugada syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Brugada syndrome in the following publications (PMID:14676229;PMID:15136511;PMID:17698727;PMID:18752142;PMID:20129283). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at